Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1 antibodies has been identified. These antibodies can protect against lentiviral infection in nonhuman primates (NHPs), suggesting that passive antibody transfer would prevent HIV-1 transmission in humans. To incr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of virology 2014-11, Vol.88 (21), p.12669-12682
Main Authors: Rudicell, Rebecca S, Kwon, Young Do, Ko, Sung-Youl, Pegu, Amarendra, Louder, Mark K, Georgiev, Ivelin S, Wu, Xueling, Zhu, Jiang, Boyington, Jeffrey C, Chen, Xuejun, Shi, Wei, Yang, Zhi-Yong, Doria-Rose, Nicole A, McKee, Krisha, O'Dell, Sijy, Schmidt, Stephen D, Chuang, Gwo-Yu, Druz, Aliaksandr, Soto, Cinque, Yang, Yongping, Zhang, Baoshan, Zhou, Tongqing, Todd, John-Paul, Lloyd, Krissey E, Eudailey, Joshua, Roberts, Kyle E, Donald, Bruce R, Bailer, Robert T, Ledgerwood, Julie, Mullikin, James C, Shapiro, Lawrence, Koup, Richard A, Graham, Barney S, Nason, Martha C, Connors, Mark, Haynes, Barton F, Rao, Srinivas S, Roederer, Mario, Kwong, Peter D, Mascola, John R, Nabel, Gary J
Format: Article
Language:English
Subjects:
Animals
Antibodies, Neutralizing - administration & dosage
Antibodies, Neutralizing - genetics
Antibodies, Neutralizing - immunology
HIV Antibodies - administration & dosage
HIV Antibodies - genetics
HIV Antibodies - immunology
HIV-1 - genetics
HIV-1 - immunology
Human immunodeficiency virus 1
Immunization, Passive - methods
Macaca mulatta
Male
Molecular Sequence Data
Primates
Sequence Analysis, DNA
Simian Acquired Immunodeficiency Syndrome - prevention & control
Simian/human immunodeficiency virus
Vaccines and Antiviral Agents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1 antibodies has been identified. These antibodies can protect against lentiviral infection in nonhuman primates (NHPs), suggesting that passive antibody transfer would prevent HIV-1 transmission in humans. To increase the protective efficacy of such monoclonal antibodies, we employed next-generation sequencing, computational bioinformatics, and structure-guided design to enhance the neutralization potency and breadth of VRC01, an antibody that targets the CD4 binding site of the HIV-1 envelope. One variant, VRC07-523, was 5- to 8-fold more potent than VRC01, neutralized 96% of viruses tested, and displayed minimal autoreactivity. To compare its protective efficacy to that of VRC01 in vivo, we performed a series of simian-human immunodeficiency virus (SHIV) challenge experiments in nonhuman primates and calculated the doses of VRC07-523 and VRC01 that provide 50% protection (EC50). VRC07-523 prevented infection in NHPs at a 5-fold lower concentration than VRC01. These results suggest that increased neutralization potency in vitro correlates with improved protection against infection in vivo, documenting the improved functional efficacy of VRC07-523 and its potential clinical relevance for protecting against HIV-1 infection in humans. In the absence of an effective HIV-1 vaccine, alternative strategies are needed to block HIV-1 transmission. Direct administration of HIV-1-neutralizing antibodies may be able to prevent HIV-1 infections in humans. This approach could be especially useful in individuals at high risk for contracting HIV-1 and could be used together with antiretroviral drugs to prevent infection. To optimize the chance of success, such antibodies can be modified to improve their potency, breadth, and in vivo half-life. Here, knowledge of the structure of a potent neutralizing antibody, VRC01, that targets the CD4-binding site of the HIV-1 envelope protein was used to engineer a next-generation antibody with 5- to 8-fold increased potency in vitro. When administered to nonhuman primates, this antibody conferred protection at a 5-fold lower concentration than the original antibody. Our studies demonstrate an important correlation between in vitro assays used to evaluate the therapeutic potential of antibodies and their in vivo effectiveness.
ISSN:0022-538X
1098-5514
DOI:10.1128/JVI.02213-14